hit counter
ADMA Biologics, Inc. (ADMA) Stock News Sentiment & Price - Sentifly
ADMA - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



ADMA Biologics, Inc. (ADMA)

USA
Biotechnology
NASDAQ
ADMA Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ADMA Latest news
GlobeNewsWire
Neutral
ADMA Biologics Announces Closing of $57.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
2021-10-25 16:01

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 25, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the closing of its previously announced underwritten public offering of 50 million shares of its common stock at a public offering price of $1.00 per share, in addition to the exercise in full of the underwriters' option to purchase an additional 7.5 million shares of common stock. The gross proceeds from the exercise of the overallotment option were $7.5 million, bringing the total gross proceeds to ADMA from the offering to $57.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

PennyStocks
Positive
Best Penny Stocks to Watch as The Market Turns Bullish
2021-10-22 09:28

Penny stocks are seeing heightened momentum, which companies are you watching? The post Best Penny Stocks to Watch as The Market Turns Bullish appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

GlobeNewsWire
Neutral
ADMA Biologics Announces Data Presented at the 2021 ISIRV-WHO Conference
2021-10-22 07:00

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 22, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that a poster presentation was made at the virtual 2021 International Society for Influenza and other Respiratory Virus Diseases - World Health Organization (ISIRV-WHO) Conference. The abstract and poster presentation detailed the use of ASCENIV TM, a novel intravenous immune globulin (IGIV) human-slra, as concomitant therapy in a 70-year-old African American male with a history of bronchiectasis who presented with severe respiratory viral disease and confirmed COVID-19 infection.

GlobeNewsWire
Neutral
ADMA Biologics Announces Pricing of Public Offering for $50 Million of Common Stock
2021-10-21 09:00

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 21, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today priced its previously announced underwritten public offering of 50 million shares of its common stock at a public offering price of $1.00 per share, resulting in gross proceeds of approximately $50 million before deducting underwriting discounts and commissions and other estimated offering expenses.

Pulse2
Negative
ADMA Stock: Why It Fell Today
2021-10-21 08:09

The stock price of ADMA Biologics Inc (NASDAQ: ADMA) fell by over 8% pre-market today. This is why it happened.

GlobeNewsWire
Neutral
ADMA Biologics Announces Proposed Public Offering of Common Stock
2021-10-20 16:01

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 20, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it intends to offer shares of its common stock for sale in an underwritten public offering. The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15 percent of the number of shares of common stock sold in connection with the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

GlobeNewsWire
Neutral
ADMA Biologics Announces a Poster Presentation at the 2021 International Society for Influenza and other Respiratory Virus Diseases - World Health Organization Conference
2021-10-19 07:00

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 19, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that a poster presentation will be made at the virtual 2021 International Society for Influenza and other Respiratory Virus Diseases - World Health Organization (ISIRV-WHO) Conference, which will take place on October 19-22. The case documents the use of ASCENIV™, a novel intravenous immune globulin (IGIV) human-slra, as concomitant therapy in a patient presenting with severe respiratory viral disease and COVID-19 infection.

GlobeNewsWire
Neutral
ADMA Biologics Strengthens its Board of Directors with the Appointment of Young T. Kwon, Ph.D.
2021-10-18 07:00

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 18, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the appointment of Young T. Kwon, Ph.D., to its Board of Directors. Dr. Kwon is a highly accomplished corporate executive in the life sciences and biotechnology space. He brings over a decade of expertise in strategic advising, corporate finance and business development transactions to ADMA's Board.

GlobeNewsWire
Neutral
ADMA Biologics Announces the Presentation of Real-World Experience in the Management of Respiratory Syncytial Virus (RSV) Presented at IDWeek 2021
2021-10-04 07:00

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced on-demand access to an exclusive educational event at IDWeek 2021 on respiratory viral infections, presented by nationally recognized clinical experts Dr. Michael Ison from Northwestern University and Dr. Jolan Walter from the University of South Florida and Johns Hopkins All Children's Hospital. During the live presentation and question and answer session, Dr. Walter discussed real-world experiences in patients that were successfully treated with ADMA's ASCENIV™, a novel intravenous immunoglobulin (IVIG) product with a unique composition. The two cases presented detailed scenarios in which ASCENIV administration demonstrated notable benefits in the clinical course of two children diagnosed with primary immunodeficiency (PI) a

GlobeNewsWire
Neutral
ADMA Biologics Announces Presentation on Respiratory Viral Infections at IDWeek 2021
2021-10-01 07:00

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 01, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced an exclusive educational event at IDWeek 2021 on respiratory viral infections, presented by nationally recognized clinical experts Dr. Michael Ison from Northwestern University and Dr. Jolan Walter from the University of South Florida and Johns Hopkins All Children's Hospital. Two leading experts in the management of respiratory syncytial virus (RSV) and other respiratory viruses in immunocompromised patients will discuss today's key clinical challenges and emerging treatment strategies. A novel intravenous immunoglobulin (IVIG) product with a unique composition will be introduced, including patient cases.

Loading more news...